System suitability raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-12. Anything still debated is marked as such rather than presented as settled.
Routine quality control monitors retention time shifts, baseline noise, system pressure, and peak shape. Trends can reveal column aging, mobile phase preparation errors, detector drift, or sample degradation. Corrective actions may include replacing the column, preparing fresh mobile phase, or recalibrating the detector. Stability testing often uses HPLC to measure parent compound loss and degradation product formation. Open questions remain about how accelerated stability results extrapolate to long-term storage under varied conditions.
Quality control for HPLC testing combines scheduled checks, documented procedures, and review of results. Before sample analysis, system suitability testing confirms that the instrument, column, and method meet predefined criteria. Common criteria include resolution between critical peaks, retention time precision, peak tailing, and theoretical plate count. Failure triggers investigation before results are reported. Records link raw data, calculations, instrument logs, and analyst identity to each batch, supporting audits and repeat analysis.
Method validation evaluates accuracy, precision, specificity, linearity, range, detection limit, quantitation limit, and robustness. Regulatory guidance for pharmaceuticals, foods, and environmental testing defines expected documentation and acceptance criteria. Verification confirms that a validated method works in a specific laboratory with its own instruments and reagents. Calibration curves use reference standards with known purity and traceability, while measurement uncertainty is estimated from validation data, control charts, and collaborative studies. The scope of validation depends on the method's intended use.
System suitability testing is performed before and during analytical runs to confirm that the instrument and method are working as expected. Typical checks include retention time, peak area precision, resolution between critical pairs, tailing factor, and theoretical plate count. Acceptance criteria are set in the method or pharmacopeial monograph. If a suitability check fails, the run may be rejected and the instrument or sample preparation may need investigation. This practice helps prevent release of data from a system that has drifted out of control.
Quality control samples are inserted at intervals to monitor accuracy and precision throughout a batch. Blank samples detect contamination, while spiked samples assess recovery from the sample matrix. Calibration standards establish the relationship between detector response and concentration, and control samples are prepared independently from them whenever possible. Laboratories also participate in proficiency testing and maintain audit trails, instrument logs, and reagent records. Ongoing review of control charts can reveal trends before they cause out-of-specification results.
Method validation demonstrates that an HPLC procedure is suitable for its intended purpose. Common validation parameters include accuracy, precision, specificity, linearity, range, limit of detection, limit of quantification, and robustness. Accuracy reflects agreement with a reference value, while precision describes repeatability under defined conditions. Specificity shows whether the method can measure the analyte in the presence of impurities or matrix components. Validation documents are reviewed before a method is used for routine testing or regulatory submissions.
| Property | Value | Notes |
|---|---|---|
| Retention time RSD | ≤1% for five replicate injections | Typical criterion; method-specific limits apply. |
| Resolution | ≥1.5 between critical pair | Baseline separation is generally desired. |
| Tailing factor | ≤2.0 | Measures peak symmetry. |
| Theoretical plates | ≥2000 per column | Method-dependent; higher values indicate greater efficiency. |
| Peak area RSD | ≤2% for replicate injections | Reflects autosampler and detector precision. |
Developing an HPLC test begins with defining the analytes, matrix, and required reporting limits. Chemists select a separation mode, column chemistry, mobile phase composition, flow rate, and detection wavelength or mass transition. Experiments then adjust these variables to achieve adequate retention, resolution, and peak shape. System suitability tests confirm that the instrument and method perform consistently before sample analysis. Without suitable resolution, quantitative results may be unreliable. Preliminary runs often use scouting gradients to locate retention windows.
Validation establishes that a method is suitable for its intended purpose. Typical parameters include accuracy, precision, specificity, linearity, range, limit of detection, limit of quantification, robustness, and stability of standards and samples. Acceptance criteria are defined in advance, and results are documented in a validation report. Regulatory guidance for pharmaceuticals, foods, and environmental testing differs, so the applicable framework must be identified. Ongoing verification uses control samples and trend charts after validation. Method transfer to another laboratory may require partial revalidation.
Validation demonstrates that a method is suitable for its intended use. Typical performance characteristics include accuracy, precision, specificity, linearity, range, limit of detection, limit of quantitation, and robustness. Regulators and standards organizations provide frameworks, but specific requirements depend on the application and jurisdiction. System suitability tests are run before sample analysis to confirm resolution, peak symmetry, retention time repeatability, and sensitivity. A validated method is not permanently fixed; changes may require partial or full revalidation.
Routine HPLC testing depends on controlled reagents, calibrated instruments, and documented procedures. Columns degrade over time, so retention times and peak shapes are monitored for drift. Mobile phases are filtered and degassed to prevent pump damage and detector noise. Reference standards must be traceable and stored under suitable conditions. Data handling systems record injections, calculations, and audit trails. Quality control samples interspersed with unknowns help detect errors during a run.
Developing an HPLC method begins with defining the purpose, such as quantifying a main component, measuring impurities, or confirming identity. Analysts select separation mode, column, mobile phase, detection, and sample preparation based on analyte properties and matrix. Experiments vary solvent strength, pH, buffer type, and temperature to achieve resolution between critical peaks. The goal is a robust method that produces reliable results across instruments and operators. Method development often involves trial runs and statistical optimization.
Regulatory and pharmacopeial texts shape how HPLC testing is performed and documented. The International Council for Harmonisation provides validation guidance, while pharmacopeias publish general chromatography chapters and monographs for specific materials. Accreditation standards such as ISO/IEC 17025 address laboratory competence and traceability. Inspectors may review instrument qualification, analyst training, reference material control, and electronic records. Open questions include how best to validate methods for new complex products and how to handle automated data processing. Laboratories generally resolve these issues through risk assessment, method lifecycle management, and documented scientific justification.
In quality control laboratories, HPLC testing supports batch release, raw material checks, stability studies, and impurity profiling. A validated method defines sample preparation, instrument settings, calibration, and acceptance criteria. Analysts compare results with specifications and investigate out-of-specification outcomes before a batch is approved. Documentation includes chromatograms, integration records, audit trails, and reagent details. Because results influence product decisions, laboratories follow formal quality systems and data integrity rules. The exact tests and limits depend on the material, its intended use, and the applicable regulatory framework.
Method validation examines whether an HPLC procedure is suitable for its intended purpose. Common parameters include accuracy, precision, specificity, linearity, range, detection limit, quantification limit, and robustness. Accuracy describes closeness to a true or accepted value, while precision describes agreement among repeated measurements. Specificity shows whether the method can measure the analyte without interference from related substances. Robustness tests small deliberate changes in flow, temperature, or solvent composition. Validation is not a one-time event; methods may need partial revalidation after changes to instruments, columns, sample handling, or specification limits. Regulatory guidance provides frameworks, but some details remain method-specific.
System suitability testing is performed before and during analytical runs to confirm that the instrument and method are working as expected. Common checks include retention time, peak area, resolution between critical pairs, tailing factor, and theoretical plate count. Results are compared with predefined limits, and a failed check requires investigation before sample results are reported. Quality control samples at low, middle, and high concentrations are injected at intervals to monitor accuracy and precision. Blank injections detect carryover and contamination, while control charts track performance over time.
Data handling and documentation are central to HPLC quality control. Electronic systems should have audit trails that record changes to methods, sequences, and results. Integration parameters, such as peak baseline and threshold, can affect reported areas and must be defined in advance. Out-of-specification results trigger a structured investigation that may include reanalysis, instrument checks, and review of sample preparation. Regulatory inspections often examine raw data, audit trails, and training records to verify that reported results are traceable and reliable.
The MEROPS protease database includes the following ten families of asparagine peptide lyases, which are included in 6 different clans of proteases. Proteolytic enzymes are classified into families based on sequence similarity. Each family includes proteolytic enzymes with homologous sequences and common catalytic type. Clans are groups of proteolytic enzymes families with related structures, where catalytic type is not conserved. *Not yet included in IUBMB recommendations. The ten different families of asparagine peptide lyases are distributed in three different types: Viral coat proteins Autotransporter proteins Intein-containing proteins There are five families of viral coat proteins (N1, N2, N8, N7 and N5), two families of autotransporter proteins (N6 and N4) and three families of intein-containing proteins (N9, N10 and N11).
Alfred Stracher (1931-2013) was an American biochemist and the founder and editor-in-chief of Drug Delivery. During his lifetime, he was Distinguished Professor of Biochemistry at SUNY Downstate Medical Center. Alfred Stracher was born in Albany, New York in 1931. He graduated from Rensselaer Polytechnic Institute in 1952 with a Bachelor of Science in Chemistry. He received his PhD in Chemistry from Columbia University in 1956.
Amyloid beta (Aβ, Abeta or beta-amyloid) denotes peptides of 36–43 amino acids that are the main component of the amyloid plaques found in the brains of people with Alzheimer's disease. The peptides derive from the amyloid-beta precursor protein (APP), which is cleaved by beta secretase and gamma secretase to yield Aβ in a cholesterol-dependent process and substrate presentation. Both neurons and oligodendrocytes produce and release Aβ in the brain, contributing to formation of amyloid plaques. Aβ molecules can aggregate to form flexible soluble oligomers which may exist in several forms. It is now believed that certain misfolded oligomers (known as "seeds") can induce other Aβ molecules to also take the misfolded oligomeric form, leading to a chain reaction akin to a prion infection. The oligomers are toxic to nerve cells. The other protein implicated in Alzheimer's disease, tau protein, also forms such prion-like misfolded oligomers, and there is some evidence that misfolded Aβ can induce tau to misfold. A study has suggested that APP and its amyloid potential is of ancient origins, dating as far back as early deuterostomes.
BIA Separations was formed in 1998 by a group of scientists in Ljubljana, Slovenia to commercialize a new chromatographic resin based on monolith technology. Monolithic resin was developed independently by three different laboratories in late 1980s led by Hjertén, Švec and Tennikova. The company was one of the few Slovenian companies to receive venture capital funding at that time-Horizonte Venture Management realizing the potential of monoliths made the initial investment in the company. During that year, BIA Separations released its first commercial product marketed under the trade name of CIM (Convective Interaction Media). The new technique was named HPMC (High Performance Monolith Chromatography). During the 1999 and 2000s, the company promoted this new platform technology to the scientific and business community and registered several patents. In 2007 the company headquarters moved to Villach, Austria. In 2011 BIA Separations entered a strategic partnership with Japan Synthetic Rubber Corporation, a Japanese company producing synthetic materials. A strategic partnership agreement with Showa Denko K.K. (SDK) was signed in 2012.
Sources: en.wikipedia.org
AAA proteases use the energy from ATP hydrolysis to translocate a protein inside the proteasome for degradation. Cdc48p/p97 functions as a hexameric AAA+ ATPase that provides the mechanical force necessary for substrate dislocation. Its activity is tightly regulated by ATP binding and hydrolysis, which induce conformational changes required for protein unfolding and extraction. The HbYX motif plays a crucial role in regulating this process by mediating interactions between Cdc48p/p97 and downstream effectors such as the 20S proteasome or specific cofactors (e.g., Ufd1/Npl4). This interaction facilitates substrate transfer from Cdc48p/p97 to the proteasome, ensuring efficient protein degradation. Given its pivotal role in protein homeostasis, Cdc48p/p97 has been implicated in a wide range of cellular processes beyond ERAD, including autophagy, mitochondrial quality control, and DNA repair. The dysregulation of its function, particularly through mutations affecting the ATPase domain or HbYX-mediated interactions, has been linked to neurodegenerative diseases and cancer.
BIA Separations was formed in 1998 by a group of scientists in Ljubljana, Slovenia to commercialize a new chromatographic resin based on monolith technology. Monolithic resin was developed independently by three different laboratories in late 1980s led by Hjertén, Švec and Tennikova. The company was one of the few Slovenian companies to receive venture capital funding at that time-Horizonte Venture Management realizing the potential of monoliths made the initial investment in the company. During that year, BIA Separations released its first commercial product marketed under the trade name of CIM (Convective Interaction Media). The new technique was named HPMC (High Performance Monolith Chromatography). During the 1999 and 2000s, the company promoted this new platform technology to the scientific and business community and registered several patents. In 2007 the company headquarters moved to Villach, Austria. In 2011 BIA Separations entered a strategic partnership with Japan Synthetic Rubber Corporation, a Japanese company producing synthetic materials. A strategic partnership agreement with Showa Denko K.K. (SDK) was signed in 2012.
Activity-based proteomics, or activity-based protein profiling (ABPP) is a chemoproteomic strategy that employs modular probes to directly assess the functional state of enzymes within complex proteomes. Unlike expression-based proteomics, which measures protein abundance, ABPP provides information about catalytic activity, thereby enabling researchers to distinguish between active and inactive forms of enzymes. This functional perspective has proven valuable for identifying drug targets, mapping ligandable sites, and understanding enzyme regulation in physiological and pathological contexts. By covalently modifying active sites, activity-based probes (ABPs) allow selective tagging, enrichment, and isolation of proteins, reducing the complexity of proteomic samples and facilitating downstream analysis. ABPP has been applied across diverse biological systems, including cells, tissues, and whole organisms, and has contributed to advances in biomarker discovery, drug development, and in vivo imaging.
Sources: en.wikipedia.org
The predecessor to the CAD, termed an evaporative electrical detector, was first described by Kaufman in 2002 at TSI Inc in US patent 6,568,245 and was based on the coupling of liquid chromatographic approaches to TSI's electrical aerosol measurement (EAM) technology. At around the same time Dixon and Peterson at California State University were investigating the coupling of liquid chromatography to an earlier version of TSI's EAM technology, which they called an aerosol charge detector. Subsequent collaboration between TSI and ESA Biosciences Inc. (now part of Thermo Fisher Scientific), led to the first commercial instrument, the Corona CAD, which received both the Pittsburgh Conference Silver Pittcon Editor's Award (2005) and R&D 100 award (2005). Continued research and engineering improvements in product design resulted in CADs with ever increasing capabilities. The newest iterations of the CAD are the Thermo Scientific Corona Veo Charged Aerosol Detector, Corona Veo RS Charged Aerosol Detector and Thermo Scientific Vanquish Charged Aerosol Detectors.
The first National Air Pollution Symposium in the United States was held in 1949 and hosted by Stanford Research Institute (now SRI International). At first, smaller governments were responsible for the passage and enforcement of such legislation. The main purpose of the Air Pollution Control Act of 1955 was to provide research assistance to find a way to control air pollution from its source. A total of $5 million was granted to the public health service for a five-year period to conduct this research. According to a private website, the amount was $3 million allotted per year for the five-year period of research.
Commenting on the assessment of the Tusk's government during the election, political scientist Gavin Rae argued that it showed misalignment with its promises from the 2023 Polish parliamentary election, and continuity with the right-wing policies of the previous government led by Law and Justice:There has been little progress on women’s and LGBT rights. Despite the propaganda about its economic record, many Poles have had to work even harder to maintain their basic living standards, with 40% of people forced to restrict their spending to make ends meet. With Tusk introducing a new round of deregulation, public services – the health service in particular – have continued to deteriorate, leaving many with inadequate care.
BOP (benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate) is a reagent commonly used for the synthesis of amides from carboxylic acids and amines in peptide synthesis. It can be prepared from 1-hydroxybenzotriazole and a chlorophosphonium reagent under basic conditions. This reagent has advantages in peptide synthesis since it avoids side reactions like the dehydration of asparagine or glutamine residues. BOP has used for the synthesis of esters from the carboxylic acids and alcohols. BOP has also been used in the reduction of carboxylic acids to primary alcohols with sodium borohydride (NaBH4). Its use raises safety concerns since the carcinogenic compound HMPA is produced as a stoichiometric by-product. PyBOP, a related phosphonium reagent for amide bond formation PyAOP, a related phosphonium reagent for amide bond formation
Sources: en.wikipedia.org
System suitability is typically performed before each batch or according to the validated method and laboratory procedure. Some long runs include periodic checks during analysis. The required frequency depends on regulatory expectations and method performance.
Retention time drift can result from changes in mobile phase composition, column temperature, pump flow, or column age. A gradual shift often points to column degradation. A sudden shift may indicate a leak, mixing error, or incorrect mobile phase.
Retention time alone cannot confirm identity because different compounds may elute at similar times. Coupling HPLC with mass spectrometry or comparing against authenticated standards increases confidence. Confirmation usually requires orthogonal data.
Method validation is the documented process of showing that an HPLC procedure produces reliable results for a defined purpose. It examines parameters such as accuracy, precision, specificity, linearity, and robustness. Regulators and quality systems often require validation before routine use.